DB:G5B

Stock Analysis Report

Executive Summary

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities.


Snowflake Analysis

Excellent balance sheet with moderate growth potential.

Share Price & News

How has Global Blood Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: G5B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

G5B

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

49.9%

G5B

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: G5B exceeded the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: G5B exceeded the German Market which returned 13.7% over the past year.


Shareholder returns

G5BIndustryMarket
7 Day0%-2.3%-0.2%
30 Day-10.8%-3.2%0.3%
90 Day30.7%6.3%3.7%
1 Year49.9%49.9%8.6%8.4%17.2%13.7%
3 Year178.8%178.8%44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Global Blood Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Global Blood Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: G5B (€66) is trading below our estimate of fair value (€202.06)

Significantly Below Fair Value: G5B is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: G5B is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: G5B is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate G5B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: G5B is overvalued based on its PB Ratio (6.7x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Global Blood Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

61.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: G5B is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: G5B is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: G5B's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if G5B's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if G5B's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: G5B is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Global Blood Therapeutics performed over the past 5 years?

-39.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: G5B is currently unprofitable.

Growing Profit Margin: G5B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: G5B is unprofitable, and losses have increased over the past 5 years at a rate of -39.1% per year.

Accelerating Growth: Unable to compare G5B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: G5B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: G5B has a negative Return on Equity (-33.43%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Global Blood Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: G5B's short term assets ($615.8M) exceed its short term liabilities ($41.2M).

Long Term Liabilities: G5B's short term assets ($615.8M) exceed its long term liabilities ($28.1M).


Debt to Equity History and Analysis

Debt Level: G5B is debt free.

Reducing Debt: G5B has not had any debt for past 5 years.


Balance Sheet

Inventory Level: G5B has a low level of unsold assets or inventory.

Debt Coverage by Assets: G5B's debt is covered by short term assets (assets are 1.7333313508335E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: G5B has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if G5B has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Global Blood Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate G5B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate G5B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if G5B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if G5B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of G5B's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Ted Love (60yo)

5.7yrs

Tenure

US$10,260,240

Compensation

Dr. Ted W. Love, M.D., serves as Director at Portola Pharmaceuticals, Inc. since September 2019. Dr. Love is a recognized industry leader with experience in the discovery and development of high impact med ...


CEO Compensation Analysis

Compensation vs Market: Ted's total compensation ($USD10.26M) is above average for companies of similar size in the German market ($USD2.27M).

Compensation vs Earnings: Ted's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ted Love
President5.7yrsUS$10.26m1.8% $71.8m
Jeffrey Farrow
Chief Financial Officer3.8yrsUS$3.33m0.056% $2.2m
Tricia Suvari
Chief Legal Officer & Secretary3.3yrsUS$3.64m0.019% $761.5k
Jung Choi
Chief Business & Strategy Officer4.8yrsUS$3.28m0.31% $12.3m
David Johnson
Chief Commercial Officer1.9yrsUS$4.39m0.022% $871.4k
David Phillips
Founder & Advisor9.1yrsno datano data
Matthew Jacobson
Founder & Advisor9.1yrsno datano data
Andrej Sali
Founder & Advisor9.1yrsno datano data
Peter Radovich
Senior Vice President of Operations3.4yrsUS$1.44mno data
Lesley Calhoun
Senior VP of Finance & Chief Accounting Officer3.4yrsno data0.0055% $220.1k

4.3yrs

Average Tenure

53yo

Average Age

Experienced Management: G5B's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ted Love
President5.7yrsUS$10.26m1.8% $71.8m
Mark Perry
Lead Independent Director0yrsUS$441.34k0.044% $1.7m
Wendy Yarno
Independent Director2.2yrsUS$428.84kno data
Glenn Pierce
Independent Director4yrsUS$433.84kno data
Philip Pizzo
Director4.4yrsUS$432.84kno data
Scott Morrison
Independent Director4.1yrsUS$443.84kno data
Dawn Svoronos
Independent Director1.2yrsUS$743.62kno data
Willie Brown
Director5.1yrsUS$431.84k0.036% $1.4m

4.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: G5B's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.6%.


Top Shareholders

Company Information

Global Blood Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Global Blood Therapeutics, Inc.
  • Ticker: G5B
  • Exchange: DB
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.298b
  • Listing Market Cap: US$3.981b
  • Shares outstanding: 60.23m
  • Website: https://www.gbt.com

Number of Employees


Location

  • Global Blood Therapeutics, Inc.
  • 171 Oyster Point Boulevard
  • Suite 300
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GBTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2015
G5BDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2015
0IVZLSE (London Stock Exchange)YesCommon StockGBUSDAug 2015

Biography

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 22:40
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.